Emerging Targets in Cancer Drug Resistance

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582722

Authors

Shashank Kumar

Prem Prakash Kushwaha

Sanjay Gupta

Affiliations

Soon will be listed here.

Abstract

Drug resistance is a complex phenomenon that frequently develops as a failure to chemotherapy during cancer treatment. Malignant cells increasingly generate resistance to various chemotherapeutic drugs through distinct mechanisms and pathways. Understanding the molecular mechanisms involved in drug resistance remains an important area of research for identification of precise targets and drug discovery to improve therapeutic outcomes. This review highlights the role of some recent emerging targets and pathways which play critical role in driving drug resistance.

Citing Articles

Cytotoxic naphtho- and benzofurans from an endophytic fungus Epicoccum nigrum Ann-B-2 associated with Annona squamosa fruits.

Elnaggar M, Fayez S, Anwar A, Ebada S Sci Rep. 2024; 14(1):4940.

PMID: 38418706 PMC: 10901772. DOI: 10.1038/s41598-024-55168-5.

Drug resistance mechanisms in cancers: Execution of pro-survival strategies.

Dhanyamraju P J Biomed Res. 2024; 38(2):95-121.

PMID: 38413011 PMC: 11001593. DOI: 10.7555/JBR.37.20230248.

Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.

Sharma N, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar P Cancers (Basel). 2024; 16(4).

PMID: 38398072 PMC: 10886629. DOI: 10.3390/cancers16040680.

Understanding the Combined Effects of High Glucose Induced Hyper-Osmotic Stress and Oxygen Tension in the Progression of Tumourigenesis: From Mechanism to Anti-Cancer Therapeutics.

G G, Shinde P, John S, C S, Mishra R Cells. 2023; 12(6).

PMID: 36980166 PMC: 10047272. DOI: 10.3390/cells12060825.

Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance.

Han E, Kim D, Cho Y, Lee S, Kim J, Kim H Molecules. 2023; 28(3).

PMID: 36770754 PMC: 9920864. DOI: 10.3390/molecules28031087.

References

Triller N, Korosec P, Kern I, Kosnik M, Debeljak A . Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer. 2006; 54(2):235-40. DOI: 10.1016/j.lungcan.2006.06.019. View

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Chan K, Lu R, Chang J, Kan Y . NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A. 1996; 93(24):13943-8. PMC: 19474. DOI: 10.1073/pnas.93.24.13943. View

To K, Leung W, Ng S . Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015; 338(2):222-31. DOI: 10.1016/j.yexcr.2015.09.011. View

Longley D, Ferguson P, Boyer J, Latif T, Lynch M, Maxwell P . Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res. 2001; 7(11):3533-9. View

Lokman N, Ween M, Oehler M, Ricciardelli C . The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011; 4(2):199-208. PMC: 3170418. DOI: 10.1007/s12307-011-0064-9. View

Cazenave L, Moscow J, Myers C, Cowan K . Glutathione S-transferase and drug resistance. Cancer Treat Res. 1989; 48:171-87. DOI: 10.1007/978-1-4613-1601-5_11. View

Wang Y, Bernhardy A, Cruz C, Krais J, Nacson J, Nicolas E . The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016; 76(9):2778-90. PMC: 4874568. DOI: 10.1158/0008-5472.CAN-16-0186. View

Hui R, Francis R, Guest S, Costa J, Gomes A, Myatt S . Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008; 7(3):670-8. DOI: 10.1158/1535-7163.MCT-07-0397. View

10.

Gilbert L, Hemann M . DNA damage-mediated induction of a chemoresistant niche. Cell. 2010; 143(3):355-66. PMC: 2972353. DOI: 10.1016/j.cell.2010.09.043. View

11.

Ukmar G, Melloni G, Raddrizzani L, Rossi P, Di Bella S, Pirchio M . PATRI, a Genomics Data Integration Tool for Biomarker Discovery. Biomed Res Int. 2018; 2018:2012078. PMC: 6051285. DOI: 10.1155/2018/2012078. View

12.

Barabas K, Milner R, Lurie D, Adin C . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2009; 6(1):1-18. DOI: 10.1111/j.1476-5829.2007.00142.x. View

13.

Stover E, Konstantinopoulos P, Matulonis U, Swisher E . Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016; 22(23):5651-5660. DOI: 10.1158/1078-0432.CCR-16-0247. View

14.

Chen C, Lin Y, Chen C, Chen Y . Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. J Biomed Sci. 2018; 25(1):30. PMC: 5877395. DOI: 10.1186/s12929-018-0430-8. View

15.

Yee S, Gong L, Badagnani I, Giacomini K, Klein T, Altman R . SLC19A1 pharmacogenomics summary. Pharmacogenet Genomics. 2010; 20(11):708-15. PMC: 2956130. DOI: 10.1097/FPC.0b013e32833eca92. View

16.

Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L . Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma. J Exp Clin Cancer Res. 2017; 36(1):111. PMC: 5559827. DOI: 10.1186/s13046-017-0581-6. View

17.

Katz E, Dubois-Marshall S, Sims A, Faratian D, Li J, Smith E . A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010; 103(3):401-10. PMC: 2920017. DOI: 10.1038/sj.bjc.6605763. View

18.

Liu X, Wei L, Zhao B, Cai X, Dong C, Yin F . Low expression of KCNN3 may affect drug resistance in ovarian cancer. Mol Med Rep. 2018; 18(2):1377-1386. PMC: 6072180. DOI: 10.3892/mmr.2018.9107. View

19.

Deffie A, McPherson J, Gupta R, Hedley D, GOLDENBERG G . Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol. 1992; 70(5):354-64. DOI: 10.1139/o92-055. View

20.

Kwon H, Roh M, Oh S, Kim S, Kim M, Kim J . Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007; 18(3):504-9. DOI: 10.1093/annonc/mdl430. View